Your browser doesn't support javascript.
loading
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Mann, Douglas L; Greene, Stephen J; Givertz, Michael M; Vader, Justin M; Starling, Randall C; Ambrosy, Andrew P; Shah, Palak; McNulty, Steven E; Mahr, Claudius; Gupta, Divya; Redfield, Margaret M; Lala, Anuradha; Lewis, Gregory D; Mohammed, Selma F; Gilotra, Nisha A; DeVore, Adam D; Gorodeski, Eiran Z; Desvigne-Nickens, Patrice; Hernandez, Adrian F; Braunwald, Eugene.
Affiliation
  • Mann DL; Department of Medicine, Washington University, St. Louis, Missouri. Electronic address: dmann@wustl.edu.
  • Greene SJ; Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina.
  • Givertz MM; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Vader JM; Department of Medicine, Washington University, St. Louis, Missouri.
  • Starling RC; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
  • Ambrosy AP; Division of Research, Kaiser Permanente Northern California, Oakland, California.
  • Shah P; Inova Heart and Vascular Institute, Falls Church, Virginia.
  • McNulty SE; Duke Clinical Research Institute, Duke University, Durham, North Carolina.
  • Mahr C; Department of Medicine, University of Washington, Seattle, Washington.
  • Gupta D; Department of Medicine, Emory University, Atlanta, Georgia.
  • Redfield MM; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
  • Lala A; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Lewis GD; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Mohammed SF; MedStar Washington Hospital Center, Washington, DC.
  • Gilotra NA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • DeVore AD; Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina.
  • Gorodeski EZ; Department of Medicine, Harrington Heart and Vascular Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • Desvigne-Nickens P; Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Baltimore, Maryland.
  • Hernandez AF; Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina.
  • Braunwald E; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
JACC Heart Fail ; 8(10): 789-799, 2020 10.
Article in En | MEDLINE | ID: mdl-32641226
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Angiotensin Receptor Antagonists / Aminobutyrates / Heart Failure Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: JACC Heart Fail Year: 2020 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Angiotensin Receptor Antagonists / Aminobutyrates / Heart Failure Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: JACC Heart Fail Year: 2020 Document type: Article Country of publication: